Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Global Blood Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Global Blood Therapeutics Inc. market cap is $4.62B.
What is the 52-week high for Global Blood Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Global Blood Therapeutics Inc. 52 week high is $73.02 as of September 06, 2025.
What is the 52-week low for Global Blood Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Global Blood Therapeutics Inc. 52 week low is $21.65 as of September 06, 2025.
What is Global Blood Therapeutics Inc. stock price today?
Global Blood Therapeutics Inc. stock price today is $68.49.
What was Global Blood Therapeutics Inc. stock price yesterday?
Global Blood Therapeutics Inc. stock price yesterday was $68.48.
What is the PE ratio of Global Blood Therapeutics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Global Blood Therapeutics Inc.’s P/E ratio is -13.70.
What is the Price-to-Book ratio of Global Blood Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Global Blood Therapeutics Inc. P/B ratio is 38.9280.
What is the 50-day moving average of Global Blood Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Global Blood Therapeutics Inc. 50-day moving average is $63.02.